Schrödinger (SDGR) Rallies On Tectora Deal But Is The Upside Already Priced In

Why Schrödinger Stock Just Moved

Schrödinger (SDGR) jumped after investors reacted to its role in forming Tectora, where the company contributed two early-stage small molecule programs in exchange for an ownership stake, potential milestones, and royalties.

The Tectora announcement lands on top of a sharp rebound in Schrödinger’s trading, with a 7 day share price return of 24.64% and a 90 day share price return of 51.84% pointing to building momentum, even though the 5 year total shareholder return decline of 60.28% shows longer term holders are still climbing out of a deep hole.

Scan Schrödinger alongside other fast-moving compounders with resilient fundamentals by reviewing the hand picked 33 high quality undervalued stocks that are drawing fresh attention from investors right now.

Schrödinger now trades above the average analyst target, yet appears to screen at an intrinsic discount of about 41%. Is the market re-rating getting ahead of the fundamentals, or is it still underpricing the risks?

Most Popular Narrative: 15% Overvalued

Schrödinger last closed at $23.93 against a widely followed fair value estimate of $20.88. The current rally is running ahead of that central narrative while still anchored to detailed cash flow and margin assumptions.

Strong pipeline advancement and early clinical success, such as positive Phase I data for SGR-1505, positions the company to secure additional milestone payments, royalties, and out-licensing deals, creating potential for substantial long-term revenue growth and more predictable future cash flows.

See why 27 investors see Schrödinger as 15% overvalued.

Result: Fair Value of $20.88 (OVERVALUED)

Still, the story can break if Schrödinger’s software growth leans too heavily on existing clients and if milestone dependent drug discovery income continues to inject volatility into cash flows.

Find out about the key risks to this Schrödinger narrative.

Another View: Schrödinger Through The Cash Flow Lens

The consensus narrative has Schrödinger trading about 14.6% above a $20.88 fair value, yet the SWS DCF model points in the opposite direction. On that framework, the shares at $23.93 sit roughly 40.6% below an estimated future cash flow value of $40.29. Which story do you trust more: the earnings multiple or the cash flows?

To see how that cash flow view is built from the ground up, and how sensitive it is to small changes in assumptions, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Schrödinger for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 33 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Sentiment around Schrödinger is clearly divided, which is exactly why it helps to move fast, stress test the assumptions yourself, and weigh both the 1 key reward and 2 important warning signs.

Looking for more Schrödinger-sized opportunities?

If you only stop at Schrödinger, you risk missing other ideas that match your style, your risk tolerance, and your income goals across the market.

• Target steady compounders with strong fundamentals by scanning a curated 33 high quality undervalued stocks that could fit a long term buy-and-hold watchlist.
• Lock in potential income ideas by reviewing a focused 6 dividend fortresses built for investors who want yields without ignoring balance sheet strength.
• Protect your downside by filtering for 11 resilient stocks with low risk scores that aim to prioritise resilient finances and more measured share price swings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com